D. E. Shaw & Co., Inc. Bei Gene, Ltd. Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $432,693 - $549,708	2,727 New	2,727 $491,000
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $13.3 Million - $19.5 Million	-51,120 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $11.3 Million - $16.2 Million	51,120 New	51,120 $13.2 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $645,541 - $798,018	-5,256 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $431,464 - $706,204	4,032 Added 329.41%	5,256 $737,000
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $319,586 - $397,148	-2,094 Reduced 63.11%	1,224 $211,000
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $541,070 - $769,099	-3,548 Reduced 51.67%	3,318 $510,000
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $1.05 Million - $1.51 Million	-13,173 Reduced 65.74%	6,866 $671,000
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $1.33 Million - $2.07 Million	20,039	20,039 $2.07 Million

254

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.